BioNTech partners with MediLink, pays $70M upfront to go up against Daiichi Sankyo in HER3news2023-10-12T12:58:08+00:00October 12th, 2023|Endpoints News|
#EuroBio23: The downturn, taking risks and the ‘biotech mafia’news2023-10-12T11:31:28+00:00October 12th, 2023|Endpoints News|
Astria licenses atopic dermatitis drug for $305M upfront from Ichnos, prices $64M stock offernews2023-10-12T11:25:05+00:00October 12th, 2023|Endpoints News|
Alvotech’s Reykjavik manufacturing doldrums continue with CRL for Stelara biosimilarnews2023-10-12T11:12:39+00:00October 12th, 2023|Endpoints News|
Illumina receives EU order to divest Grailnews2023-10-12T10:07:25+00:00October 12th, 2023|Endpoints News|
Delaware judge approves Mallinckrodt’s second bankruptcy plan since 2020news2023-10-11T19:29:28+00:00October 11th, 2023|Endpoints News|
Biogen cuts almost one-third of Reata’s staff following $7B buyoutnews2023-10-11T19:12:54+00:00October 11th, 2023|Endpoints News|
Supernus drafts NFL sportscaster Jay Glazer in media and social blitz for ADHD med Qelbreenews2023-10-11T19:01:37+00:00October 11th, 2023|Endpoints News|
GSK settles another heartburn drug Zantac cancer case in Californianews2023-10-11T18:48:36+00:00October 11th, 2023|Endpoints News|
CMS postpones national coverage determination for PrEP, says decision is ‘forthcoming’news2023-10-11T18:25:15+00:00October 11th, 2023|Endpoints News|
